OBJECTIVE:To explore the effects of Xuebijing injection on serum inflammatory factors in patients with severe pneumonia( SP) . METHODS:126 patients with SP were randomly divided into two groups, with control group administered with conventional anti-infective and phlegm-expelling agents, mechanical ventilation, symptomatic and supportive treatment, whereas the patients in the treatment group were intravenously administered with 100 ml add-on Xuebijing injection b. i. d for 14 days. Serum interleukin-6 ( IL-6 ) , interleukin-10 ( IL-10 ) and tumor necrosis factor-α( TNF-α) levels in the two groups were compared; scoring for acute lung injury, multiple organs dysfunction syndrome(MODS) and systemic inflammatory response syndrome(SIRS) were performed. RESULTS: At 7 and 14 days of treatment, IL-6 and TNF-αlevels, lung injury score, MODS score and SIRS score in the treatment group were significantly lower than in the control group ( P<0�05 );with regard to IL-10 , no significant differences were noted for both groups before and after treatment or between the two groups. CONCLUSIONS:Xuebijing injection can inhibit the release of inflammatory factors and significantly improve the prognosis of patients with SP.%目的：探讨血必净注射液对重症肺炎患者炎症因子的影响。方法：将126例患者采用随机双盲试验设计分为治疗组和对照组，对照组给予常规抗感染、祛痰、机械通气、对症支持治疗，治疗组在此基础上加用血必净注射液100 ml静脉滴注、2次/d，疗程为14 d。比较2组患者血清中白细胞介素-6（IL-6）、白细胞介素-10（IL-10）、肿瘤坏死因子-α（TNF-α）水平，并进行急性肺损伤评分、多器官功能障碍综合征评分（ MODS评分）和全身炎症反应综合征评分（ SIRS评分）。结果：治疗7 d和14 d后，治疗组患者IL-6、TNF-α、肺损伤评分、MODS评分和SIRS评分比对照组明显下降（P＜0�05）；2组患者治疗前后及2组间IL-10水平比较均无明显差异。结论：血必净注射液可抑制炎症因子释放，显著改善重症肺炎患者预后。
展开▼
